Study Summary
This trial will compare a Continuous Glucose Monitor (CGM) with Sensor Augmented Mode (SAM) therapy to see which is more effective in Type 1 Diabetes Mellitus (T1DM). It will also study how different psychological factors affect the performance of these systems, in order to optimize glycemic control and reduce the psychological impact of the system.
- Type 1 Diabetes
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: 7 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Escalation
1 of 2
De-escalation
1 of 2
Experimental Treatment
100 Total Participants · 2 Treatment Groups
Primary Treatment: Sensor-Augmented Pump therapy · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| Alabama | 33.3% |
| North Carolina | 33.3% |
| Virginia | 33.3% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| University of Virginia Center for Diabetes Technology | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Frequently Asked Questions
How many respondents are engaging in this research endeavor?
"Affirmative. The clinicaltrials.gov website states that this trial is presently recruiting participants, with 100 test subjects being sought from a single medical centre since the initial posting on September 4th 2020 and recent edit on January 13th 2022." - Anonymous Online Contributor
Is enrollment currently available for those wishing to participate in this trial?
"As per the information on clinicaltrials.gov, this trial is currently searching for participants. It was first announced in September 2020 and revised as recent as January 2022." - Anonymous Online Contributor